Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Martin J. van den Bent, C. Mircea S. Tesileanu, Wolfgang Wick, Marc Sanson, Alba Ariela Brandes, Paul M. Clement, Sarah Erridge, Michael A. Vogelbaum, Anna K. Nowak, Jean Français Baurain, Warren P. Mason, Helen Wheeler, Olivier L. Chinot, Sanjeev Gill, Matthew Griffin, Leland Rogers, Walter Taal, Roberta Rudà, Michael Weller, Catherine McBainJaap Reijneveld, Roelien H. Enting, Francesca Caparrotti, Thierry Lesimple, Susan Clenton, Anja Gijtenbeek, Elizabeth Lim, Ulrich Herrlinger, Peter Hau, Frederic Dhermain, Iris de Heer, Kenneth Aldape, Robert B. Jenkins, Hendrikus Jan Dubbink, Johan M. Kros, Pieter Wesseling, Sarah Nuyens, Vassilis Golfinopoulos, Thierry Gorlia, Pim French, Brigitta G. Baumert

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study'. Together they form a unique fingerprint.

Medicine & Life Sciences